Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Plavix Scripts Fall To 35% On Heels Of Generic Entry

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Total prescriptions of generic clopidogrel were roughly 38,600 on Aug. 18, compared to approximately 21,100 for Plavix, according to IMS data presented at a Manhattan federal court hearing Aug. 21

You may also be interested in...



Plavix Injunction Ruling Will Include Irreparable Harm Interpretation

If a preliminary injunction is granted, Apotex says it would suffer irreparable harm of $4 bil.; Sanofi/Bristol counter it would be only $25 mil.

Plavix Hearing Scheduled For Aug. 18 After Sanofi/Bristol File Preliminary Injunction

Apotex launch of generic clopidogrel is the “largest ‘at-risk’ infringing launch of all time,” Sanofi/Bristol court filing claims.

Apotex Launches Generic Plavix

Bristol-Myers Squibb, Sanofi-Aventis may seek preliminary injunction against Apotex.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS064720

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By